Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Management Inc (NQ: CGEM )

8.110 +0.010 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 225,876
Open 8.040
Bid (Size) 7.670 (3)
Ask (Size) 8.160 (1)
Prev. Close 8.100
Today's Range 7.730 - 8.315
52wk Range 7.730 - 13.74
Shares Outstanding 199,873,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Cullinan Oncology Q3 Earnings
Via Benzinga
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire

Performance

YTD
-24.06%
-24.06%
1 Month
-15.43%
-15.43%
3 Month
-23.35%
-23.35%
6 Month
-36.19%
-36.19%
1 Year
-30.39%
-30.39%

More News

Read More
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Analyst Ratings for Cullinan Oncology
Via Benzinga
Analyst Ratings for Cullinan Oncology
Via Benzinga
Analyst Expectations for Cullinan Oncology's Future
Via Benzinga
Expert Ratings for Cullinan Oncology
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
4 Analysts Have This to Say About Cullinan Oncology
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About Cullinan Oncology
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
Why Shares of Cullinan Oncology Jumped This Week
Via The Motley Fool
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
From Cullinan Oncology, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.